ESMO 2026 | IMA203CD8, a TCR T-cell therapy, in PRAME-positive solid tumors
Lawrence Fong, MD, Fred Hutchinson Cancer Center, Seattle, WA, discusses updated results from a Phase I basket trial (NCT03686124) of IMA203CD8, a T-cell receptor (TCR) T-cell therapy co-expressing a PRAME-directed TCR and CD8αβ, in heavily pretreated patients with relapsed or refractory PRAME-positive solid tumors. The safety profile was manageable, with expected lymphodepletion-related cytopenias and mostly low-grade cytokine release syndrome. Objective responses, including complete and durable responses, were seen across diverse tumor types, such as melanoma, synovial sarcoma, and gynecological cancers. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
IMA203CD8 is a cell therapy for solid tumors. And this is based upon a prior cell therapy that’s called Anzu-Cel that has actually entered registration trials. But this cell product is trying to improve upon those results by introducing a new cell. By introducing a CD8 molecule into that cell therapy. And so the Phase 1 clinical trial is reporting on the clinical activity of these cells in patients across multiple diseases...
IMA203CD8 is a cell therapy for solid tumors. And this is based upon a prior cell therapy that’s called Anzu-Cel that has actually entered registration trials. But this cell product is trying to improve upon those results by introducing a new cell. By introducing a CD8 molecule into that cell therapy. And so the Phase 1 clinical trial is reporting on the clinical activity of these cells in patients across multiple diseases. And impressively, the clinical trial shows that this cell product has activity not just in sarcoma or melanoma, but some of the more difficult to treat cancers like ovarian cancer and endometrial cancer. And so this is really a great foundation from which we could think about developing this cell product more in additional solid tumors, as well as the ones that they studied in the Phase 1 clinical trial.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
